Golimumab as the First Monthly Subcutaneous Fully Human Anti-TNF-α Antibody in the Treatment of Inflammatory Arthropathies

Abstract

Golimumab (Simponi™, Centocor Ortho Biotech Inc., PA, USA) is the first transgenic human monoclonal antibody against TNF-α that has been approved in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Golimumab is synthesized using conventional hybridoma technique after immunizing transgenic mice containing human immunoglobulin genes. The constant region of golimumab is identical to that of infliximab, but the variable regions of golimumab have fully human sequences. In this article, we present the pharmacodynamic and pharmacokinetic properties as well as the clinical efficacy and tolerability of golimumab.

KEYWORDS::

• human monoclonal antibody
• monthly subcutaneous injection
• rheumatoid arthritis
• SmartJect autoinjector
• TNF-α
• transgenic

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.